Alteon reports Phase IIa data for ALT-711

ALT said that in a U.S. Phase IIa study of ALT-711, its advanced glycosylation end-product crosslink breaker (A.G.E. crosslink breaker), patients receiving ALT-711 had a statistically significant redu...